BRAINSTORM CELL THERAPEUTICS INC.
For the period ended Jun 30, 2026. Filed Aug 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 14, 2026
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Financial Statements
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of June 30, 2026
U.S. DOLLARS IN THOUSANDS
(UNAUDITED)
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
As of June 30, 2026
U.S. DOLLARS IN THOUSANDS
(UNAUDITED)
INDEX
| | Page |
|---|---|
| | |
| Interim Condensed Consolidated Balance Sheets | 6 |
| | |
| Interim Condensed Consolidated Statements of Comprehensive Loss | 7 |
| | |
| Interim Condensed Statements of Changes in Stockholders’ Equity (Deficit) | 8 |
| | |
| Interim Condensed Consolidated Statements of Cash Flows | 10 |
| | |
| Notes to Interim Condensed Consolidated Financial Statements | 11 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.